Celgene, a Summit, New Jersey-headquartered biopharmaceutical company, has appointed Scott Smith as president and chief operating officer (COO), effective April 1, 2017, following the retirement of current president and COO, Jacqualyn Fouse, PhD. Dr. Fouse has decided to retire from Celgene effective June 30, 2017 but will continue to serve as president and COO until April 1. She will serve as a strategic advisor to the management team through to June 30, but will not stand for reelection to the Celgene board of directors.
Dr. Fouse joined Celgene in 2010 as chief financial officer and was appointed president of Celgene's Hematology & Oncology Franchise in 2014. In 2016 she was promoted to president and COO and was elected to Celgene's board of directors.
Mr. Smith, who will take over as president and COO in April, joined Celgene in 2008. He has thirty years of experience in the biopharmaceutical industry spanning commercial, business strategy, and general management roles across multiple countries and therapeutic areas. Before joining Celgene, Mr. Smith served as global commercial head for Biovail.
In addition to Mr. Smith’s appointment, Celgene has also appointed Terrie Curran as president, Global Inflammation & Immunology Franchise, effective April 1, 2017. Ms. Curran joined Celgene in 2013 as the US commercial head of the I&I Franchise. In early 2016, Ms. Curran was promoted to head of worldwide commercial markets for the I&I Franchise. Prior to joining Celgene, Ms. Curran was a senior vice president at Merck & Co., where she led the Global Women's Health franchise from 2009-2013.